Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion...
Keep Reading →
August 26 - Hedge Funds, News
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc.
Keep Reading →
August 13 - Hedge Funds, News
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list.
Keep Reading →
July 8 - News
In this article, we will be taking a look at the 10 Best Innovative Healthcare Stocks to Buy Now. The U.S.
Keep Reading →
July 7 - Hedge Funds, News
In this article, we will take a look at some of the best large cap stocks under $30 that are currently offering attractive upside potential.
Keep Reading →
June 5 - Hedge Funds, News
In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.
Keep Reading →
May 12 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now.
Keep Reading →
May 2 - News
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Keep Reading →
April 30 - Hedge Funds, News
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Genmab A/S is among the best biotech stocks.
Keep Reading →
April 24 - News
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Right Now.
Keep Reading →
April 23 - Hedge Funds, News
In this article, we will take a look at 15 large cap stocks under $30 that currently offer attractive upside potential to investors.
Keep Reading →
March 25 - Hedge Funds, News
Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years.
Keep Reading →
February 20 - News
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Keep Reading →
February 19 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) Q4 2025 Earnings Call Transcript February 17, 2026Genmab A/S misses on earnings expectations. Reported EPS is $0.4035 EPS, expectations were $0.46.
Keep Reading →
February 18 - News, Transcripts
In this article, we will look at the 10 High Growth International Stocks to Buy Now.
Keep Reading →
February 11 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in.
Keep Reading →
February 10 - News
In this article, we will look at the 12 Best Healthcare Stocks Under $50 to Invest In.
Keep Reading →
February 9 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C.
Keep Reading →
January 30 - News
In this article, we will take a look at 10 High Growth European Stocks To Buy.
Keep Reading →
January 28 - Hedge Funds, News
Orbis Investment Management released its Q4 2025 investor letter for “Orbis SICAV International Equity Fund”.
Keep Reading →
January 22 - Hedge Fund Investor Letters, News
We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Genmab A/S is one of the best cancer stocks on our list.
Keep Reading →
January 20 - News
In this article, we will be taking a look at the Top 10 Oncology Stocks to Buy Now.
Keep Reading →
January 19 - Lists, News
We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB.
Keep Reading →
January 15 - News, Stock Analysis
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua...
Keep Reading →
December 31 - Hedge Fund Investor Letters, News
Genmab A/S (NASDAQ:GMAB) Q3 2025 Earnings Call Transcript November 8, 2025 Operator: Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call.
Keep Reading →
November 11 - News, Transcripts
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C.
Keep Reading →
October 28 - News
In this article, we will look at the 9 Most Profitable Biotech Stocks to Buy.
Keep Reading →
October 27 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now.
Keep Reading →
September 17 - News
In this article, we will look at the top 12 Affordable Biotech Stocks to Invest In Now.
Keep Reading →
September 16 - Hedge Funds, News
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Genmab A/S stands fifth among them.
Keep Reading →
September 11 - News
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025.
Keep Reading →
September 10 - Hedge Funds, News
We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks.
Keep Reading →
August 29 - News
We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them.
Keep Reading →
August 29 - News
In this article, we will be taking a look at the 11 Cheap Biotech Stocks to Buy According to Hedge Funds.
Keep Reading →
August 27 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now.
Keep Reading →
August 12 - News
In this article, we will look at the 10 Most Undervalued Biotech Stocks to Buy Now.
Keep Reading →
August 11 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) Q2 2025 Earnings Call Transcript August 7, 2025Genmab A/S beats earnings expectations. Reported EPS is $0.54, expectations were $0.39.
Keep Reading →
August 9 - News, Transcripts
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now.
Keep Reading →
July 28 - News
We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Genmab A/S stands eighth on our list and has recently opened new sites in the US.
Keep Reading →
July 25 - News
In this article, we will look at the 10 Most Profitable Biotech Stocks to Invest in Now.
Keep Reading →
July 25 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now.
Keep Reading →
July 25 - News
Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
Keep Reading →
July 24 - News
In this article, we will take a detailed look at the 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen.
Keep Reading →
July 23 - Hedge Funds, News
In this article, we will look at the 12 Best Extremely Profitable Stocks to Buy Right Now.
Keep Reading →
July 23 - Hedge Funds, News
Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential.
Keep Reading →
July 10 - News
Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential.
Keep Reading →
July 10 - News
In this article, we will look at the 10 Best Growth Stocks to Buy With Huge Upside Potential.
Keep Reading →
July 9 - Hedge Funds, News
In this article, we will look at the 13 Cheap Healthcare Stocks with Huge Upside Potential.
Keep Reading →
July 9 - Hedge Funds, News
On Tuesday, June 3, Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” rating.
Keep Reading →
June 4 - News
Genmab A/S (NASDAQ:GMAB) has announced promising new data for its investigational antibody-drug conjugate, rinatabart sesutecan (Rina-S), in advanced endometrial cancer.
Keep Reading →
June 3 - News
Hedge Fund Resource Center 
